Go to Top
Small Cap Biotechs

Recent Updates

For Biotech and Pharmaceutical Companies

Looking for Financing, PR or Investor Relations Services?

We facilitate introductions to leading hedge funds who share your company's best interests and may be interested in investing in you. We also bump shoulders with some of the premier Investor Relations & PR firms in the United States. We've a track record of success which supports these relationships, and a network that feeds our success. If you have a company in need of greater visibility or capital investment, we'd like to hear from you.

Contact Us

Biotech News and Updates

Sientra (NASDAQ: SIEN) : DD and More

December 13, 2015
Comments Off on Sientra (NASDAQ: SIEN) : DD and More

A few excerpts: PennyStockHaven: From Sientra’s (SIEN) 8-K filing from October 30th, 2015: We continue to be well funded with a cash and cash equivalents balance of $148.9 million as of September 30, 2015. Earlier this week we paid in full our term loans totaling $24.5 million, and as a result the company has no outstanding debt obligations. Insider Monkey: At the end of the third quarter, a total of 10

Read More

SANUWAVE (SNWV): U.S. Patent to Sterilize Blood Using SNWV’s Shock Wave Technology

April 11, 2013
Comments Off on SANUWAVE (SNWV): U.S. Patent to Sterilize Blood Using SNWV’s Shock Wave Technology

SANUWAVE Health, Inc. (OTCBB:SNWV) has received a patent issued by the U.S. Patent and Trademark Office entitled “Method and Devices for Cleaning and Sterilization with Shock Waves.” The claims of the patent (patent number 8,343,420) relate to a new method that sterilizes blood by applying external shock waves to destroy blood pathogens contained in bags, pipes and tubes.The patent has a term extending to July 2031 . Joseph Chiarelli ,

Read More

BioCryst Pharmaceuticals (BCRX): Update Regarding Peramivir

April 1, 2013
Comments Off on BioCryst Pharmaceuticals (BCRX): Update Regarding Peramivir

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases. BioCryst announced that it received a preliminary comment letter from the FDA that outlines a pathway by which BioCryst could file a New Drug Application (NDA) seeking regulatory approval of its drug candidate intravenous peramivir. Pre-NDA meeting to reach agreement on a complete NDA submission and to address review

Read More

Cell Therapeutics, Inc.(CTIC): $15MM Loan Financing Agreement

March 28, 2013
Comments Off on Cell Therapeutics, Inc.(CTIC): $15MM Loan Financing Agreement

Cell Therapeutics, Inc.  (CTIC) announced that it has entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. for a senior secured term loan of up to $15 million. The first $10 million of the term loan was funded on March 27, 2013, and the remaining $5 million is available at the Borrowers’ option at any time from November 30, 2013 through December 15, 2013, subject to

Read More

AntriaBio (ANTB): An Opportunity

March 17, 2013
Comments Off on AntriaBio (ANTB): An Opportunity

Novo Nordisk – the world’s largest insulin producer – and major diabetes drug manufacturers – could see BILLIONS in recurring revenue dry up as a small, California-based biotech company advances a technology that promises to change diabetes treatment. Over $100,000,000 has been invested in developing this super-drug that threatens to make products like Sanofi’s $6 BILLION-A-YEAR basal insulin – ‘Lantus’ – OBSOLETE. The Company that’s making executives in the world’s

Read More

Oncolytics Biotech (ONCY): Positive REOLSYIN Clinical Trial Data from Phase 2 Study

February 8, 2013
Comments Off on Oncolytics Biotech (ONCY): Positive REOLSYIN Clinical Trial Data from Phase 2 Study

Oncolytics Biotech Inc. (NASDAQ: ONCY) is focused on the development of oncolytic viruses for use as cancer therapeutics. The Company’s lead product, REOLYSIN®, a proprietary formulation of the human reovirus, is currently in late stage (Phase III) clinical testing in head and neck cancers. REOLYSIN® has been utilized in nearly thirty clinical trials including translational, Phase I, Phase II (single arm and randomized), and Phase III studies in a broad range of

Read More

Biotech Stocks Reviews